公开(公告)号：US20170335406A1

公开(公告)日：2017-11-23

申请号：US15661021

申请日：2017-07-27

申请人： John S. Condeelis ,  Sumanta Goswami ,  Frank Gertler ,  Paola Nistico

发明人： John S. Condeelis ,  Sumanta Goswami ,  Frank Gertler ,  Paola Nistico

IPC分类号： C12Q1/68 ,  A61K31/713 ,  G01N33/50 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K31/713 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5011 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57496

摘要： Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.

公开(公告)号：US09803196B2

公开(公告)日：2017-10-31

申请号：US14007932

申请日：2012-03-28

申请人： Richard Morgan

发明人： Richard Morgan

IPC分类号： G01N33/574 ,  C07K14/47 ,  C12N15/113 ,  C07K14/705 ,  C07K16/18

CPC分类号： C12N15/113 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C12N15/1135 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57492 ,  G01N2800/52

摘要： Compositions and methods which inhibit the expression of the TMEM92 gene or which inhibits the function of die TMEM92 protein can be used for treating, diagnosing and monitoring disease, for example cancer.

公开(公告)号：US20170299595A1

公开(公告)日：2017-10-19

申请号：US15514438

申请日：2015-09-28

申请人： The Regents of the University of California ,  Cedars-Sinai Medical Center

发明人： Hsian-Rong Tseng ,  Jiaoti Huang ,  Edwin M. Posadas ,  Jiefu Chen ,  Hao Ho ,  Zunfu Ke ,  Ker-Chau Li ,  Yi-Tsung Lu ,  Jake Lichterman ,  Min Song ,  Leland W.K. Chung

IPC分类号： G01N33/574 ,  G01N15/10

CPC分类号： G01N33/57434 ,  G01N15/10 ,  G01N15/1475 ,  G01N33/56966 ,  G01N33/57488 ,  G01N2015/1006 ,  G01N2015/1488 ,  G01N2015/1493 ,  G01N2015/1497 ,  G01N2800/56

摘要： A method, system and computer-readable medium for assessing a disease condition of a cancer of a subject, including: receiving a blood sample from the subject; isolating a plurality of circulating tumor cells (CTCs) from the blood sample; measuring at least one of cell or cell nucleus sizes of each of the plurality of CTCs; determining a measured CTC size distribution of the plurality of CTCs based on the measuring; comparing the measured CTC size distribution to a reference CTC size distribution using a computer; and assigning the disease condition of the cancer of the subject based on the comparing.

公开(公告)号：US20170296679A1

公开(公告)日：2017-10-19

申请号：US15261357

申请日：2016-09-09

申请人： Intuitive Surgical Operations, Inc.

发明人： Jonathan Sorger

IPC分类号： A61K49/00 ,  G01N33/574 ,  A61K9/00 ,  A61J1/18 ,  C09B23/10

CPC分类号： A61K49/0052 ,  A61K9/0019 ,  A61K49/0032 ,  A61K49/0034 ,  C09B23/0025 ,  C09B23/0066 ,  G01N33/57434

摘要： Compositions and methods for visualizing tissue under illumination with fusion compounds of near-infrared radiation using near IR, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are provided.

公开(公告)号：US20170281801A1

公开(公告)日：2017-10-05

申请号：US15623353

申请日：2017-06-14

申请人： On Target Laboratories, LLC

发明人： Sumith A. Kularatne ,  Pravin Gagare

IPC分类号： A61K49/00 ,  C07K5/09

CPC分类号： A61K49/0052 ,  A61K49/0017 ,  A61K49/0032 ,  A61K49/0056 ,  A61K49/16 ,  C07D209/20 ,  C07K5/06026 ,  C07K5/0606 ,  C07K5/06078 ,  C07K5/06095 ,  C07K5/06121 ,  C07K5/06147 ,  C07K5/06156 ,  C07K5/0806 ,  C07K5/0812 ,  C07K5/0817 ,  C07K5/1019 ,  C07K7/02 ,  C07K7/06 ,  C12Y304/17021 ,  G01N21/6428 ,  G01N33/57434 ,  G01N33/57492 ,  G01N2021/6439 ,  G01N2333/948

摘要： The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

公开(公告)号：US09766244B2

公开(公告)日：2017-09-19

申请号：US14412235

申请日：2013-07-01

申请人： THE GENERAL HOSPITAL CORPORATION

发明人： Daniel A. Haber ,  Shyamala Maheswaran ,  David T. Miyamoto

IPC分类号： A61K39/00 ,  G01N33/574 ,  A61K31/167 ,  A61K31/496 ,  A61K31/58 ,  C12Q1/68

CPC分类号： G01N33/57434 ,  A61K31/167 ,  A61K31/496 ,  A61K31/58 ,  A61K2039/505 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  G01N2333/705

摘要： Provided herein are assays and methods related to determining a ratio of expression levels of PSA/PSMA or determining the expression level of PSMA in circulating tumor cells for diagnosis and/or for the purpose of monitoring treatment efficacy for prostate cancers that are likely hormone resistant.

公开(公告)号：US20170234883A1

公开(公告)日：2017-08-17

申请号：US15415379

申请日：2017-01-25

申请人： Genentech, Inc.

发明人： Mark S. DENNIS ,  Bonnee RUBINFELD ,  Paul POLAKIS ,  Aya JAKOBOVITS

IPC分类号： G01N33/574 ,  C07K16/40

CPC分类号： G01N33/57434 ,  A61K38/05 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6851 ,  A61K47/6869 ,  A61K47/6871 ,  A61K49/0002 ,  A61K49/0058 ,  A61K51/1045 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K16/40 ,  C07K17/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

摘要： Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.

公开(公告)号：US09725494B2

公开(公告)日：2017-08-08

申请号：US14276713

申请日：2014-05-13

申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services

发明人： Jeffrey Schlom ,  Jianping Huang

IPC分类号： G01N33/574 ,  A61K39/39 ,  A61K39/00 ,  C07K14/705 ,  A61K38/17

CPC分类号： C07K14/70503 ,  A61K38/1793 ,  A61K39/39 ,  A61K2039/55516 ,  C07K14/70578 ,  G01N33/57434 ,  G01N33/57488 ,  G01N2333/70575 ,  G01N2333/70578 ,  G01N2800/52

摘要： Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of sCD27 in a serum sample obtained from a subject and comparing that amount of sCD27 with a control value indicative of the basal level of sCD27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of sCD27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor. The disclosed methods can be used to monitoring disease progression in a subject or determine a subject's suitability for immunotherapy. Also disclosed are methods of stimulating a subject's immune system by administering a therapeutically effective amount of sCD27 or a functional fragment.

公开(公告)号：US20170199182A1

公开(公告)日：2017-07-13

申请号：US15410424

申请日：2017-01-19

申请人： Assurance LLC

发明人： Jin Po LEE

IPC分类号： G01N33/543 ,  G01N33/78 ,  G01N33/574 ,  G01N33/74

CPC分类号： G01N33/54373 ,  G01N21/78 ,  G01N33/54366 ,  G01N33/558 ,  G01N33/57434 ,  G01N33/57473 ,  G01N33/74 ,  G01N33/78 ,  G01N2021/6439 ,  G01N2021/7786 ,  G01N2021/7793 ,  G01N2021/7796 ,  Y10S435/805 ,  Y10S435/81 ,  Y10S435/97 ,  Y10S436/805 ,  Y10S436/81 ,  Y10S436/811 ,  Y10S436/813 ,  Y10S436/814 ,  Y10S436/818

摘要： The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with the immobilized calibrator agents in the standard bands to provide a known label response in the standards bands, and the downstream membrane is capable of absorbing said sample and providing the capillary flow for the sample through the upstream and test membrane.

公开(公告)号：US09694091B2

公开(公告)日：2017-07-04

申请号：US14715115

申请日：2015-05-18

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Martin G. Pomper ,  Sangeeta Ray ,  Ronnie C. Mease ,  Catherine Anne Foss

IPC分类号： A61K51/04 ,  A61K31/195 ,  C07D257/00 ,  A61K31/145 ,  A61K31/395 ,  A61K31/4402 ,  A61K38/06 ,  C07D213/38 ,  C07D215/12 ,  G01N33/574 ,  C07D257/02 ,  C07F13/00 ,  C12Q1/37 ,  G01N33/60

CPC分类号： A61K51/0472 ,  A61K31/145 ,  A61K31/195 ,  A61K31/395 ,  A61K31/4402 ,  A61K38/06 ,  A61K51/0402 ,  C07D213/38 ,  C07D215/12 ,  C07D257/00 ,  C07D257/02 ,  C07F13/00 ,  C12Q1/37 ,  G01N33/57434 ,  G01N33/60 ,  G01N2500/04 ,  A61K2300/00

摘要： The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.